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ABSTRACT
Aberrant DNA methylation has been frequently observed in many human cancers, 
including rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in 
children. To date, the expression and function of the de novo DNA methyltransferase 
(DNMT) 3B in RMS have not yet been investigated. Our study show for the first time 
a significant up-regulation of DNMT3B levels in 14 RMS tumour samples and 4 RMS 
cell lines in comparison to normal skeletal muscle. Transfection of RD and TE671 
cells, two in vitro models of embryonal RMS (ERMS), with a synthetic DNMT3B siRNA 
decreased cell proliferation by arresting cell cycle at G1 phase, as demonstrated by the 
reduced expression of Cyclin B1, Cyclin D1 and Cyclin E2, and by the concomitant up-
regulation of the checkpoint regulators p21 and p27. DNMT3B depletion also impaired 
RB phosphorylation status and decreased migratory capacity and clonogenic potential. 
Interestingly, DNMT3B knock-down was able to commit ERMS cells towards myogenic 
terminal differentiation, as confirmed by the acquisition of a myogenic-like phenotype 
and by the increased expression of the myogenic markers MYOD1, Myogenin and 
MyHC. Finally, inhibition of MEK/ERK signalling by U0126 resulted in a reduction of 
DNMT3B protein, giving evidence that DNMT3B is a down-stream molecule of this 
oncogenic pathway.
Taken together, our data indicate that altered expression of DNMT3B plays a key 
role in ERMS development since its silencing is able to reverse cell cancer phenotype 
by rescuing myogenic program. Epigenetic therapy, by targeting the DNA methylation 
machinery, may represent a novel therapeutic strategy against RMS.
INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common 
soft tissue sarcoma in childhood and adolescence, 
accounting for about 5% of malignant paediatric tumours 
[1]. The two main histological subtypes, alveolar RMS 
(ARMS) and embryonal RMS (ERMS), are associated 
with particular cytogenetic abnormalities and with 
different outcome [2]. ARMS is a high-grade malignancy 
and the majority of cases (90%) is characterized by 
either a t(2;13) or t(1;13) translocation, resulting in the 
expression of PAX3:FOXO1 or PAX7:FOXO1 fusion 
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proteins [2, 3]. ERMS, the most common RMS type, is 
associated with a more favourable outcome and commonly 
exhibits 11p15 loss of heterozygosity [2] and/or mutations 
in components of the RAS pathway [4]. Presently, there 
is a growing evidence that epigenetic mechanisms play 
an important role in cancer development, with changes in 
DNA methylation being a crucial event in the control of 
gene expression [5]. The enzymatic addition of a methyl 
group at the carbon 5 position of cytosine, in the context 
of the sequence 5’ cytosine-guanosine (CpG), controls 
the expression of many tissue-specific genes [6–8], as 
well as several important cellular functions, such as X 
chromosome inactivation and genomic imprinting [9]. 
In mammalians, methylation of DNA is catalysed by the 
DNA methyltransferase (DNMT) enzymes 1, 3A and 3B. 
DNMT1 is required for the methylation maintenance 
by preferentially methylating the unmethylated strand 
of hemimethylated DNA during DNA replication [10, 
11], whilst DNMT3A and DNMT3B are necessary 
for the establishment of de novo methylation of both 
strands during development [11]. Indeed, DNMT3A 
and DNMT3B are highly expressed in embryonic cells, 
where most new methylation events occur, and are down-
regulated in differentiated cells [11, 12]. Over-expression 
of DNMTs has been described in several human tumour 
types, including lymphomas, liver, prostate, colorectal, 
breast, lung, pancreatic and endometrial cancer [13–
18], and is generally associated with a more aggressive 
phenotype, indicating that DNMT1, 3A and 3B likely 
act as oncogenes [19]. Recent evidences suggest that a 
deregulation of the de novo DNMT enzymes contributes 
to the development of paediatric brain tumours [20]. 
Silencing of tumour suppressor genes (TSGs) by 
promoter CpG island hypermethylation seems to be 
the most probable mechanism involved in the process 
of carcinogenesis linked to epigenetic events. Indeed, 
transcriptional repression of different TSGs, such as p16/
CDKN2A, RASSF1, MLH1, etc., has been extensively 
described in several malignancies and has been mainly 
linked to the aberrant quantity/activity of DNMT3 family 
enzymes [21, 22]. DNMTs inhibit gene expression by also 
recruiting transcriptionally repressive complexes, which 
include methyl-CpG binding domain (MBD) factors, 
polycomb group (PcG) proteins and repressor factors, 
to specific DNA sites [23–27]. Distinct patterns of DNA 
hypermethylation have been found in different types of 
cancers, confirming the importance to better understand 
the molecular mechanisms that mediate epigenetic 
phenomena. Because epigenetic alterations are reversible, 
DNMTs also represent attractive therapeutic targets since 
their inhibition might have the ability to overturn tumour 
cell phenotype [28–30]. Increased DNMT1 activity in 
RMS was previously reported [31] and DNA methylation 
signatures have been recently described in ARMS 
and ERMS cases [32], suggesting that aberrant DNA 
methylation may contribute to the development of RMS. 
Indeed, hypermethylated CpG islands have been identified 
in several genes involved in skeletal muscle development 
and differentiation in both RMS cell lines and primary 
tumour samples [32–34]. Consistently, treatment with 
5-aza-2’-deoxycytidine (5-aza-dC), a general DNA 
demethylating agent, is able to suppress tumorigenicity 
and partially reactivate myogenic program in different 
RMS cell lines [34, 35]. Despite these evidences, the 
expression and the individual role of DNMT3B have not 
yet been characterised in this malignancy. Since different 
studies linked DNMT3B over-expression to gene-
specific hypermethylation during cancer development 
and progression [36, 37], we investigated the DNMT3B 
function in RMS. Our study reveals that DNMT3B levels 
are significantly up-regulated in RMS tumours and cell 
lines in comparison with normal skeletal muscle (NSM). 
Notably, DNMT3B knock-down by RNA interference is 
able to significantly arrest cell proliferation and promote 
myogenic differentiation of ERMS cell lines. Indeed, 
DNMT3B-depleted cells changed their morphology, with 
a more elongated appearance, and expressed increased 
levels of the myogenic proteins MYOD1 (myoblast 
determination protein 1) and Myogenin as well as the 
terminal differentiation marker MyHC (myosin heavy 
chain). We also suggest that DNMT3B is a down-stream 
important molecule in the mitogen-activated protein 
kinase kinase/extracellular signal-regulated kinase (MEK/
ERK) signalling pathway since treatment with U0126, a 
known inhibitor of ERK phosphorylation, drastically 
down-regulates DNMT3B protein levels in ERMS cells, 
this leading to growth arrest and terminal myogenic 
differentiation.
These findings underline how the dysregulation of 
DNA methylation is associated with RMS transformation 
and aggressiveness, and suggest that impairing DNMT3B 
activity may be a promising tool for treatment of RMS, 
especially the ERMS subtype.
RESULTS
DNMT3B quantification in RMS tumours 
and cell lines
To explore the association between DNA 
methylation and RMS, transcript levels of the de novo 
DNMT3B gene were assessed in 7 ARMS and 7 ERMS 
primary tumours by using Real Time PCR (Q-PCR). 
Expression of DNMT3B was significantly up-regulated in 
all tumour samples in comparison to NSM, used as normal 
tissue, with an average increase of 81.2±9.4 (Figure 1A). 
In accordance with previously published data [31], also 
DNMT1 mRNA levels were significantly higher in ARMS 
and ERMS tumours compared to NSM (30.5±9.0, data not 
shown). DNMT3A levels were also investigated, showing 
an up-regulation in RMS vs. NSM of 22.0±3.3 (data not 
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shown). DNMT3B over-expression was also confirmed in 
ARMS (RH4 and RH30) and ERMS (RD and TE671) cell 
lines both at mRNA and protein levels (Figure 1B and 1C).
siRNA transfection down-regulates DNMT3B 
expression and inhibits RMS cell proliferation
In order to evaluate the effect of DNMT3B enzyme 
on the phenotype of RMS cells, we used a specific small 
interfering RNA (siRNA) against DNMT3B mRNA in RD 
cell line, an in vitro model of ERMS. SiRNA transfections 
were performed in RD cells cultured in growth medium, 
i.e. supplemented with 10% serum. DNMT3B knock-down 
efficiency was assessed by using Q-PCR and western blot 
analysis at 72 h after transfection. A significant reduction 
of DNMT3B at both mRNA (0.4-fold) and protein (0.5-
fold) levels (Figure 2A and 2B) was observed in si-
DNMT3B cells compared to those transfected with the 
negative control siRNA (si-NC). Colorimetric assays 
confirmed that DNMT3B protein quantity was reduced 
about 0.5-fold after RNAi-specific silencing respect to 
mocked control (data not shown). DNMT1 and DNMT3A 
expression was not significantly perturbed by transient si-
DNMT3B transfection, this assessing a specific silencing 
(Figure 2A and 2B). Moreover, immnunoflurescence 
experiments showed that the cellular distribution of 
DNMT3B was mainly into the nucleus in mocked 
control RD cells, whilst, upon si-DNMT3B transfection, 
Figure 1: DNMT3B expression in RMS tumours and cell lines. A. Quantitative real time PCR (Q-PCR) analysis of DNMT3B 
mRNA levels in 14 RMS primary tumours (7 ARMSs and 7 ERMSs), expressed as fold increase over NSM, arbitrarily set at 1. Transcript 
levels were normalized to GAPDH mRNA and error bars represent SD of two independent Q-PCR reactions, each performed in triplicate. 
B. Q-PCR of DNMT3B mRNA levels in ARMS (RH4 and RH30) and ERMS (RD and TE671) cell lines, expressed as fold increase over 
NSM, arbitrarily set at 1. GAPDH was used as control. Bars represent mean values of three independent experiments, each performed in 
triplicate. HFM, human foetal myoblats. C. Western blot showing the expression of DNMT3B protein in RH4, RH30, RD and TE671 cell 
lines. Tubulin was used as loading control. Representative of three different experiments.
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Figure 2: DNMT3B knock-down by RNA interfering and effects on RD cell viability and morphology. A. DNMT3B 
transcript levels measured by Q-PCR at 72 h in RD cells after transfection with DNMT3B siRNA (si-DNMT3B) in comparison 
to samples transfected with non-targeting control siRNA (si-NC), arbitrarily set at 1. Specific transcript levels were normalized to 
GAPDH control mRNA. Shown are the means of four independent experiments. Error bars represent standard deviations of the means. 
Asterisks represent the statistical significance (***, p<0.001; ns, not significant). DNMT1 and DNMT3A mRNA levels were also 
analysed to check the specificity of siRNA-mediated silencing. B. Western blots showing the expression of DNMT3B protein at 72 h 
after si-DNMT3B transfection compared to si-NC cells. Tubulin was used as loading control. DNMT1 and DNMT3A protein levels 
were not perturbed by si-DNMT3B delivery. Representative of three independent experiments. C. Representative immunofluorescence 
showing the down-regulation of DNMT3B protein levels in nuclear compartment at 72 h after si-DNMT3B transfection. High levels of 
DNMT3B were evident in the nuclei of si-NC cells. D. Viability of RD cells 72 h post-transfection with DNMT3B siRNA calculated 
with respect to control si-NC cells, assessed by trypan blue exclusion staining. Results represents the mean value of four independent 
experiments ± SD. Statistical significance: **, p<0.01. E. MTT assay performed to assess relative RD cell numbers at different point 
after si-DNMT3B or si-NC transfection (0-24-48-72 h). Each point is the mean of three replicate wells ± SD and is representative of 
three independent experiments. F. Cellular morphology of si-NC and si-DNMT3B RD cells was analysed under light microscope at 20x 
magnification at 72 and 144 h after siRNA transfection. In si-DNMT3B cultures, more elongated cellular bodies were evident, many of 
which formed multinucleated myotube-like structures.
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a noticeable decline in its nuclear levels was detected 
(Figure 2C). At 72 h subsequent to transfection, direct 
counting for living cells using trypan blue dye exclusion 
test confirmed that DNMT3B depletion was able to 
drastically inhibit the proliferation potential of RD cells 
compared to si-NC cells (Figure 2D). Similar results 
were obtained by MTT assay, which showed a significant 
decrease of cellular viability/proliferation rate in si-
DNMT3 compared to si-NC transfected cultures (Figure 
2E). DNMT3B silenced cells exhibited a substantial 
change in their morphology with more elongated cellular 
bodies already after 72 h post-siRNA transfection (Figure 
2F). At 144 h after transfection, si-DNMT3B cells showed 
even lower levels of DNMT3B itself (data not shown) 
and an increased number of multinucleated myotube-like 
structures (Figure 2F), whilst si-NC had high DNMT3B 
protein levels and showed the typical round proliferative 
shape (Figure 2F). DNMT3B siRNA transfection carried 
out in a second ERMS cell line (TE671) gave overlapping 
results with a marked reduction in DNMT3B protein levels 
in western blotting and immunofluorescence experiments 
(Supplementary Figure S1A-S1B). DNMT3B knocked-
down TE671 cells also exhibited a minor cell growth rate 
(data not shown) and a more elongated morphology than 
mocked control cells (Supplementary Figure S1C) at both 
72 and 144 h post-transfection.
Decreased DNMT3B expression induces 
G1 cell cycle arrest and inhibits cell 
migration of RMS cells
To further determine whether the reduced RD cell 
growth was due to alterations in cell cycle progression, 
flow cytometry analysis was performed. Based on 
propidium iodide staining of cellular DNA content, 
DNMT3B down-regulation resulted in a significant 
increase of cell percentage in G1 phase (p<0.005) with 
a concomitant decrease of cell percentage in S and G2 
phases (G1: 78.0±2.8%, S: 15.1±2.5%, G2: 6.9±0.27%), 
whilst si-NC transfected cells rapidly divided and 
progressed through the cell cycle at high rates (G1: 
43.5±0.7%, S: 44.9±2.0%, G2: 11.6±1.3%) (Figure 3A). 
Consistent with G1 arrest, the expression of different cell 
cycle regulators was modulated with a marked decrease of 
Cyclin B1, Cyclin D1 and Cyclin E2 expression (Figure 
3B) and a simultaneous up-regulation of p21 and p27 
levels in DNMT3B depleted cells (Figure 3B). As shown 
in Figure 3B, DNMT3B knowck-down also efficiently 
abolished the phosphorylation status of retinoblastoma 
(RB) tumour suppressor (p-RB) and induced a parallel 
slight reduction in E2F1 levels (0.2-fold), this confirming 
the cell cycle block at G1 phase. In accordance with 
Western blotting expression results, immunofluorescence 
experiments also showed that si-DNMT3B transfection 
caused a strong reduction of Cyclin D1 nuclear staining 
with a dramatic up-regulation and relocalization of p21 
in the nuclear compartment (Figure 3C). Consistent with 
the RB activity in its underphosphorylated state, nuclear 
shuttling of the E2F1 transcriptional factor was not evident 
in si-DNMT3B cells compared to si-NC samples (Figure 
3C). Programmed cell death was not affected by DNMT3B 
knock-down since no significant changes in early or late 
apoptosis rates were observed in si-DNMT3B compared 
to si-NC transfected cells, as assessed by flow cytometry 
experiments (data not shown). Furthermore, the expression 
levels of some specific apoptosis markers, such as cleaved 
PARP and BcL-Xl, resulted similar in DNMT3B-depleted 
cells and in negative control samples (data not shown). 
DNMT3B silencing significantly impaired the ability 
of RD cells to migrate through the non-matrigel-coated 
membranes towards serum-containing medium with 
respect to si-NC controls (Figure 4A). Finally, when 
allowed to grow at low density, si-DNMT3B cells showed 
a lower ability to form colonies in anchorage-dependent 
experiments compared to control cells, with a 0.6-fold of 
crystal violet absorbance (Figure 4B).
Together, these results indicated that the in vitro 
under-expression of DNMT3B is able to inhibit RMS 
progression by reducing cell proliferation and migration.
DNMT3B knock-down promotes myogenic 
differentiation in RMS cells
Since si-DNMT3B transfected cells showed 
a substantial change in their morphology with the 
acquisition of a myogenic-like phenotype, the expression 
of specific muscle markers was evaluated. A sustained 
increase of MYOD1, Myogenin and MyHC at mRNA 
and protein levels was observed in both Q-PCR and 
immunoblotting assays, performed 72 h after DNMT3B 
silencing respect to si-NC transfection (Figure 5A and 
5B). In immunofluorescence experiments, MYOD1 
factor exhibited a more evident granular staining in 
nuclear envelope in si-DNMT3B transfected RD cells in 
comparison to si-NC samples (Figure 5C); furthermore, 
elongated myotube-like si-DNMT3B cells displayed a 
strong fluorescence of MyHC, a marker of committed 
muscle cells (Figure 5C), indicating that the proper 
myogenic differentiation was triggered by the reduction 
of the DNMT3B levels. TE671 cells transfected with 
si-DNMT3B also showed up-regulation of MYOD1, 
Myogenin and MyHC protein levels at 72 h post-siRNA 
injection (Supplementary Figure S1D-S1E).
Notably, the phenotypic effect of DNMT3B 
knock-down in RD cells was also observed at 144 h 
post-transfection, with higher levels of MyHC protein 
(Figure 5B), confirming that the commitment to terminal 
myogenic differentiation was preserved. Finally, we 
investigated whether DNMT3B was also involved in the 
control of specific miRNAs. Indeed, we demonstrated that 
DNMT3B depletion was able to significantly up-regulate 
the expression of miR-133a and miR-206, two well-
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established myomiRs essential in promoting muscle cell 
differentiation (Figure 5E).
Taken together, these results show that the selective 
inhibition of DNMT3B gene can effectively promote a 
sustained myogenic program in ERMS cells, by inducing 
the proper temporal expression of myogenic genes and 
miRNAs important for differentiation.
MEK/ERK inhibitor U0126 down-regulates 
DNMT3B protein expression
Since the MEK/ERK cascade is aberrantly activated 
in RMS and its inhibition has been shown to affect tumour 
growth and to rescue skeletal muscle differentiation in 
ERMS cells [38], as occurred in si-DNMT3B transfected 
cells, we studied if DNMT3B expression could be linked 
to the MEK/ERK signalling pathway. RD cells treated 
with the MEK/ERK inhibitor U0126 (10 μM) for 96 
h were able to fully differentiate, as assessed by the 
up-regulation of MYOD1, Myogenin and MyHC levels, 
by impairing DNMT3B protein expression (Figure 6A). 
Interestingly, a drastic reduction of DNMT3B enzyme 
was observed at early points of U0126 treatment (12-24 
h) in RD cells, subsequently to the down-regulation of 
ERK phosphorylation status, evident at 6 h post-exposure 
(Figure 6B). TE671 cells treated with U0126 showed 
matched results (Supplementary Figure S1F). Considering 
the evidence that U0126 treatment is able to activate p38 
kinase for promoting myosin expression in RMS cells 
[38, 39], p38 phosphorylated levels were analysed in 
DNMT3B depleted cells. A long-lasting increase of p38 
phosphorylation (p-p38) was observed in si-DNMT3B 
transfected cells in comparison to si-NC samples both at 
72 than at 144 h in RD (Figure 6C) and TE671 cell lines 
(Supplementary Figure S1G).
Altogether, these data indicate that DNMT3B is a 
down-stream component of the MEK/ERK signalling 
pathway and that abrogation of this enzyme is an essential 
Figure 3: Depletion of DNMT3B levels induces G1 arrest and alters the expression of specific cell cycle regulators in 
RD cells. A. Flow cytometry data showing percentages of cells in G1, S and G2 phases in si-DNMT3B and si-NC RD cells. Data are 
average values of three independent experiments. B. Western blot analyses of a panel of cell cycle regulatory proteins in RD cells at 72 
h after si-NC or si-DNMT3B transfection. Tubulin expression was used as the internal control. Representative blots of three independent 
experiments. C. Immunofluorescence experiments showing the expression and localization of Cyclin B1, Cyclin D1, p21, p-RB and E2F1 
proteins in RD cells at 72 h after DNMT3B or NC siRNA transfection. DAPI was used for nuclear staining. Images captured under 
ApoTome microscope at 40x magnification.
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step in the U0126-mediated capacity of ERMS cells to 
rescue myogenic differentiation program.
DISCUSSION
DNA hypermethylation, an epigenetic mechanism 
resulting in transcriptional silencing, is a common 
occurrence in tumour development [6, 40–42]. Aberrant 
methylation of CpG islands has also been observed in 
RMS [32, 43], a solid tumour characteristic of childhood 
and adolescence. Our study shows, for the first time, an 
aberrant expression of DNMT3B gene in both ARMS and 
ERMS primary tumours and cell lines. In particular, 
DNMT3B transcripts are over-expressed in RMS tumours 
compared to NSM, suggesting that high levels of this 
enzyme are important molecular features of RMS. Our 
results indicate that the inhibition of DNMT3B expression 
is a crucial step for reverting RMS cancer phenotype 
towards skeletal muscle differentiation, by restricting the 
expression of proliferative markers and up-regulating 
myogenic genes. Indeed, knock-down of DNMT3B gene 
by RNA interference impaired the in vitro tumour-
promoting potential of ERMS cells by significantly 
reducing cell proliferation, migration and colony-forming 
ability. Consistent with the marked cellular growth arrest 
at G1/S-phase transition, altered levels of proteins 
involved in the cell cycle control were observed, 
supporting a key role of DNMT3B in sustaining RMS cell 
progression. One of the potential mechanisms that 
underline the DNMT3B-mediated arrest involves the 
ability of DNMT3B siRNA to reduce the expression of 
different cyclins (Cyclin B1, Cyclin D1 and Cyclin E2) 
and to block the pRB/E2F1 pathway by inducing de-
phosphorylation of RB tumour suppressor. Indeed, 
hypophosphorylated RB represents the active form of the 
protein that is able to associate with E2F1 factor, hence 
preventing its nuclear translocation and blocking its ability 
to activate genes that are important in cell cycle 
progression [44]. The inhibition of cell proliferation was 
also confirmed at molecular levels by a significant increase 
in p21, whose up-regulation might be directly related to a 
promoter demethylation and a concomitant re-expression 
upon DNMT3B depletion. Interestingly, the efficient 
growth inhibition induced by DNMT3B knock-down was 
not associated to an increased apoptosis rate but to the 
restoration of myogenic fate in ERMS cell lines. The 
Figure 4: DNMT3B reduction correlates with altered migration and clonogenic ability of RD cells. A. Representative 
images of RD si-DNMT3B and si-NC migrated cells using the transwell migration assay (magnification of 10x). Data in the histograms are 
expressed as the means ± SD from three separate experiments, each performed in triplicate (**, p<0.01 compared with the respective si-NC 
control, arbitrarily set at 1). B. RD cells transfected with si-DNMT3B or si-NC were seeded at low concentration and allowed to grow for 8 
days to examine their colony formation capacity. Representative pictures of colonies stained with crystal violet. Colony forming efficiency 
was calculated by crystal violet absorbance from three independent experiments, each performed in triplicate (*, p<0.05 compared with the 
respective si-NC control, arbitrarily set at 1).
Oncotarget79349www.impactjournals.com/oncotarget
effect of DNMT3B in vitro down-regulation on the ARMS 
tumorigenic phenotype remains to be fully dissected, but 
preliminary results suggest that the differentiation program 
is not efficiently sustained in RH4 and RH30 cells. We can 
speculate that DNMT3B is an essential repressor of 
myogenic differentiation since forced DNMT3B down-
regulation is able to activate muscle-regulatory factors 
(MRFs) and myomiRs in ERMS cell culture models, 
irrespective of high serum concentration levels in the 
culture medium. The observed decrease of DNMT3B 
protein levels upon treatment with U0126, an inhibitor of 
MEK/ERK signalling network, whose disruption has 
previously been demonstrated to reactivate myogenesis in 
ERMS cells [38, 39], further supports the hypothesis that 
DNMT3B expression must be turned off to enable a 
proper muscular differentiation. Compared to mocked 
control cells, si-DNMT3B samples showed of a marked 
expression of MYOD1, followed by Myogenin and 
Figure 5: DNMT3B knock-down triggers myogenic differentiation in RD cells. A. Expressionof myogenic genes, MYOD1, 
Myogenin and MyHC, by Q-PCR assays in RD cells transfected with DNMT3B or NC siRNAs for 72 h. Expression of each mRNA was 
normalized to GADPH levels and plotted as fold change relative to si-NC samples. Histograms are means ± SD. Asterisks represent the 
statistical significance (**, p<0.01; ***, p<0.001). B. Western blot showing the expression of MYOD1, Myogenin and MyHC proteins 
in si-DNMT3B and si-NC RD cells at 72-144 h post-transfection. Tubulin was used as loading control. Representative of three different 
experiments. C. Immunofluorescence experiments showing the expression and localization of MYOD1 and MyHC at 72 h after DNMT3B 
or NC siRNA transfection. DAPI was used for nuclear staining. Images captured under ApoTome microscope at 40x magnification. D. 
Expression of myogenic miRNAs, miR-133a and miR-206, by Q-PCR experiments in RD cells transfected with DNMT3B or NC siRNAs 
for 72 h. Expression of each miRNA was normalized to U6 levels and plotted as fold change relative to si-NC samples. Histograms are 
means ± SD. Asterisks represent the statistical significance (**, p<0.01; ***, p<0.001).
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myomiR (miR-133a and miR-206) up-regulation. MYOD1 
is a master regulator of myogenesis, since it normally 
triggers the down-stream molecular events that switch 
myoblasts from a growing phase to a differentiated state, 
by directly promoting the expression of miR-206 and 
many other genes involved in myogenesis [45, 46]. RD 
proliferating cells show low levels of MYOD1, and 
increased abundance of this transcription factor has been 
demonstrated to fully execute the terminal myogenic 
program [47], this confirming that a controlled amount of 
MRFs is a fundamental condition for proper skeletal 
muscle differentiation in ERMS cells. Notably, DNMT3B 
silencing was maintained at 144 h after siRNA-
transfection and determined long-term changes in ERMS 
cell phenotype, as assessed by the elevated levels of 
MyHC protein, a marker of terminal myogenic 
specification. Notably, DNMT3B knock-down induced a 
sustained activation of p38 kinase, which has been 
reported to promote myogenesis and to maintain 
myogenic-related morphology in ERMS cells [38, 39]. 
Based on the present results, DNMT3B may represent a 
new important molecule explaining why ERMS cells fail 
to activate/complete the skeletal muscle differentiation 
program and to exit the cell cycle. Therefore, 
understanding the DNMT3B-mediated molecular 
mechanisms affecting these pathways may yield further 
insights into pathophysiological processes in RMS 
tumours. Several studies have suggested that the 
methylation of the enhancer/promoter regions of muscle 
regulators is a critical event in the initiation of the 
myogenic transcriptional program [48]. Alterations of 
methylation levels occurring in the promoter of the human 
MYOD1 gene have been reported in RMS tumours, with 
partially methylated MYOD1 up-stream regions present 
essentially in ERMS subtypes [33]. Human MYOD1 gene 
is located at 11p15 [49], a chromosomal region containing 
the IGF2 and H19 imprinted genes [50], whose expression 
has been found to be altered (over-expression of IGF2 and 
downregulation of H19) in a subset of ERMS tumours 
[51]. Therefore, the abnormal MYOD1 methylation 
pattern observed in RMS might be due to a generalized 
deregulation of the 11p15 imprinted region. To this 
concern, over-expressed levels of the DNMT3B might be 
directly responsible for the epigenetic deregulation 
observed in RMS, since this enzyme is responsible of de 
novo DNA methylation patterns. DNMT3B might preserve 
skeletal muscle differentiation in ERMS cells by directly 
hypermethylating DNA or by cooperating with other 
factors able to modify chromatin, such as histone 
deacetylases (HDACs) and PcG proteins [26, 27, 52]. 
Previous reports have demonstrated that the activation/
repression of muscle-related gene transcription is achieved 
by a coordinate sequence of epigenetic molecular 
mechanisms, comprehending both acetylation and 
methylation at specific 5’-flanking regulatory regions [7, 
52, 53]. In line with this observations, exposure of RMS 
cells to demethylating agents or HDAC inhibitors has been 
shown to have pro-differentiative effects in RMS cells by 
up-regulating the expression levels of different muscle-
specific coding genes and miRNAs [34, 35, 54]. 
Transcriptional repression by hypermethylation of both 
DNA and histones at the promoter/enhancer regions of 
myogenic factors and cofactors has recently been proposed 
as a potential mechanism to promote tumour formation 
and progression as well as to impair terminal 
differentiation in RMS [55–57]. Recent findings have 
Figure 6: Inhibition of MEK/ERK pathway by U0126 down-regulates DNMT3B and induces myogenic program in 
RD cells. A. Western blot showing the down-regulation of DNMT3B and the up-regulation of MYOD1, Myogenin and MyHC in RD cells 
treated with 10 μM U0126 for 96 h. Mocked control cells were treated with DMSO. Tubulin was used as loading control. Representative 
of three different assays. B. Time-course experiments showing the early decreased phosphorylation status of ERK (p-ERK) and the down-
stream reduced expression of DNMT3B protein in RD cells upon U0126 treatment for 0-6-12-24-48-96 h. Tubulin was used as loading 
control. Representative of two different assays. C. Western blot showing phosphorylated and total p38 levels in si-DNMT3B and si-NC 
RD cells at 72 and 144 h post-transfection.
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shown that DNMT3 enzymes can repress transcription in 
a methylation-independent manner [58], since their 
capacity to bind silencer complexes, comprehending MBD 
proteins, or specific transcriptional repressors [25, 59–61]. 
Indeed, in addition to the highly conserved DNMT 
catalytic domain at C-terminus [62], DNMT3 family 
proteins have at N-terminus a plant homeodomain-like 
motif, which is present in many chromatin-associated 
proteins and mediates protein-protein interactions [63]. 
So, the molecular mechanisms of DNMT3B-mediated 
transcriptional silencing at muscle-gene regulatory regions 
in RMS could be due to its potential repressor activity. 
Preliminary results indicate that DNMT3B and MYC are 
able to interact in RD cells (Megiorni & Marampon, 
unpublished data), suggesting a possible molecular 
mechanism for site-specific DNA methylation/repression 
of target genes in ERMS tumours. Bisulfite sequencing 
and chromatin immunoprecipitation assays are currently 
underway in our laboratory to characterize the possible 
epigenetic modifications at enhancer/promoter regions 
associated with MYOD1, Myogenin and MyHC 
expression in si-DNMT3B RMS cells in comparison to 
control mocked samples. Understanding the molecular 
mechanisms associated with the activated muscular 
differentiation after DNMT3B depletion is essential to 
design novel pharmacological treatments for this soft 
tissue sarcoma. Future studies will also be aimed at 
globally characterising the methylome profile in si-
DNMT3B cells in order to provide a deeper insight into 
the RMS tumorigenesis and to identify new potential 
targets for the development of more effective and less 
toxic epigenetic therapies. Indeed, 5-aza and 5-aza-dC 
DNA demethylanting agents have been approved by US 
Food and Drug Administration for clinical use but, despite 
some promising results in laboratory models and in 
haematological malignancies [64, 65], their efficacy in the 
treatment of human solid tumours is still controversial 
[66]. Furthermore, these drugs are two nucleoside 
analogues that are incorporated into nucleic acids so that 
long-term exposure induces high levels of toxicity [67]. 
Non-nucleoside compounds, which are independent of 
replication for their incorporation into DNA, or other 
molecules with a high biochemical selectivity towards 
individual human DNMT enzymes might lead to 
promising anticancer therapies [68, 69], and this also in 
RMS.
In summary, this study describes for the first time 
the over-expression of DNMT3B gene in RMS primary 
tumours and cell lines, suggesting that an aberrant 
transcriptional control mediated by this de novo DNMT is a 
key event in RMS development and progression. Altogether 
our findings also outline the potential clinical application of 
DNMT3B inhibition in cancer treatment. DNMT3B target 
therapies may represent a novel clinical approach, effective 
not only in impairing tumour growth but also in reactivating 
myogenic program, especially in ERMS subtypes.
MATERIALS AND METHODS
Patient clinical features
Fourteen RMS primary tumour samples, 7 ARMSs 
and 7 ERMSs, were obtained at diagnosis before any 
treatment from children admitted to the Department of 
Oncology at the Alder Hey Children’s NHS Foundation 
Trust, Liverpool. Histopathological diagnosis was 
confirmed using immunohistochemistry. All 7 ARMS 
cases were investigated for PAX3/7-FOXO1 translocations 
using standard FISH analysis: 5 tumours were PAX3-
FOXO1-positive, 1 was PAX7-FOXO1-positive and 1 
was fusion-negative. Patients were grouped according 
to the Intergroup Rhabdomyosarcoma Study (IRS) 
postsurgical grouping system [70]. Details of the patients 
have previously been described [35]. Institutional written 
informed consent was obtained from the patient’s parents 
or legal guardians. The study underwent ethical review 
and approval according to the local institutional guidelines 
(Alder Hey Children’s NHS Foundation Trust Ethics 
Committee, approval number 09/H1002/88). Control 
RNA was extracted from normal skeletal muscle (NSM) 
obtained from eight children undergoing surgery for non-
oncological conditions.
RNA isolation
Total RNA was extracted using TRIzol (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s 
instructions. RNA quality and quantity were checked using 
NanoDrop 2000 (Thermo Scientific, Waltham, MA).
Cell lines and cultures
Alveolar (RH4 and RH30) and embryonal (RD and 
TE671) cells were maintained in high-glucose Dulbecco’s 
modified Eagle’s medium supplemented with 10% foetal 
bovine serum (FBS), 1% v/v L-glutamine, 100 μg/ml 
streptomycin and 100 U/ml penicillin, and grown at 37°C 
in a humidified atmosphere of 5% CO2. To minimize the 
risk of working with misidentified and/or contaminated 
cell lines, we later stocked the cells used in this report 
at very low passages and used at <20 subcultures. DNA 
profiling using the GenePrint 10 System (Promega 
Corporation, Madison, WI) was carried out to authenticate 
cell cultures, comparing the DNA profile of our cell 
cultures with those found in GenBank.
Quantitative real time PCR (Q-PCR)
Total RNA (2 μg) was subjected to reverse 
transcription (RT) with High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Foster City, 
CA) according to the manufacturer's instructions. 
Quantitative Real Time PCR (Q-PCR) for human DNMT1 
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(Hs00154749_m1), DNMT3A (Hs01027166_m1), 
DNMT3B (Hs00171876_m1) and MyHC (Hs00428600_
m1) mRNAs was performed using specific TaqMan Real-
Time Gene Expression Assays (Applied Biosystems). 
Q-PCRs for human MYOD and Myogenin transcripts 
was carried out with the SensiFAST SYBR Hi-ROX Kit 
(Bioline, London, UK). Primer sequences are available 
under request. All Q-PCR assays were performed on 
a StepOne Real Time System (Applied Biosystems) 
machine. Samples were normalized according to the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA levels. RT for human miR-133a (000458) and miR-
206 (000510) was carried out with TaqMan MicroRNA 
Assay kit (Applied Biosystems) using 20 ng of total RNA 
sample and the specific stem-loop primer according to 
manufacturer’s protocols. Data were normalized to U6 
small nuclear RNA (RNU6, 001093) levels. The amount of 
each mRNA/miRNA was calculated by the comparative Ct 
method and expressed as fold change using the StepOne 
v2.3 software (Applied Biosystems). Each sample was 
run in triplicate in at least three independent experiments, 
unless specified differently in the figures.
Transient transfection
RD and TE671 cells were seeded at 4×105 cells/well 
in 6-well plates; small interfering RNA (siRNA) against 
human DNMT3B (si-DNMT3B, sc-37759 by Santa Cruz 
Biotechnology, Dallas, TX) or siRNA negative control 
(si-NC, sc-37007 by Santa Cruz Biotechnology) were 
combined with RNAiMAX (Invitrogen) and used at 60 
nM final concentration; si-DNMT3B is a pool of 3 target 
specific 19-25 nt siRNAs designed to specifically knock-
down DNMT3B gene and this product was previously 
validated in other publications [41, 71]. Cells were 
collected for cell cycle analysis, Q-PCR, western blot, 
immunofluorescence, migration, etc. at different times 
after transfection. All the experiments were performed in 
proliferating growth medium, i.e. supplemented with 10% 
FBS.
DNMT3B colorimetric quantification
The EpiQuik Dnmt3B Assay Kit (Epigentek, 
Farmingdale, NY) was used to colorimetrically measure 
the amount of DNMT3B in nuclear extracts of si-NC 
and si-DNMT3B RD cells after 72 h post-transfection, 
according to the manufacturer's instructions. Experiments 
were repeated on RD cells after two independent 
transfections.
Cell proliferation assays
Direct counting of RD and TE671 living cells was 
performed with trypan blue exclusion dye (Sigma-Aldrich, 
Saint Louis, MO) using the Countess II Automated Cell 
Counter (Thermo Fisher) at 72 h after si-DNMT3B or 
si-NC transfection. Experiments were repeated at least 
three times. Cell viability of the siRNA-transfected cells 
was determined using MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium] assay. RD cells (104) 
were plated onto 96-well plates in sextuplicates and, 
after 24 h, transfected with synthetic DNMT3B siRNA; 
mocked control cells (transfected with si-NC) and blank 
cell-free wells were also included. At designated times 
after transfection (0-24-48-72 h), 10 μl of MTT (5 mg/
ml, Sigma-Aldrich) were added to each well and plates 
were incubated at 37°C for 3 h. Media were removed and 
200 μl of DMSO was added into each well to dissolve 
the dark blue formazan crystals. Absorbance was read at 
wavelength of 550 nm, with reference at 630 nm, using 
a microtitre plate reader (SelectScience, Corston, UK). 
The percentage cellular viability was calculated with 
the appropriate controls taken into account. The results 
were plotted as means ± SD of two separate experiments 
having six determinations per assay for each experimental 
condition.
Morphological assessment of siRNA-transfected 
cells
An Axio Vert.A1 microscope (Carl Zeiss 
Microscopy, Thornwood, NY), furnished with an 
AxioCam MRc5 camera (Carl Zeiss Microscopy) was 
used to observe the morphological changes of the cells 
transfected with si-DNMT3B or si-NC siRNAs. Cells 
were photographed at 72 and 144 h post-transfection using 
a 20x magnification. Images were analysed by using the 
ImageJ software (NIH ImageJ 1.47).
Cell cycle analysis
RD and TE671 cells transfected with DNMT3B 
or NC siRNAs were counted at 72 h post-transfection 
and at least 106 cells were fixed in 70% ice-cold ethanol 
overnight at +4°C. Cell pellets were washed twice with 
ice-cold PBS and treated with RNase A (50 μg/ml) for 
30 min at 37°C. Propidium iodide (10 μg/ml) was added 
to each sample and DNA content was measured by BD 
FACSCalibur Flow Cytometer (BD Biosciences, San Jose, 
CA). Data were analysed using ModFit 3.1 software (BD 
Biosciences). Experiments were carried out three times.
Trans-well migration assay
For the cell migration assay, BD FalconTM Cell 
Culture Inserts with 8 μm pore polycarbonate filters were 
placed into a 24-well culture plate. Briefly, serum-free cell 
suspension containing 105 si-DNMT3B or si-NC RD cells 
was added to the upper compartment of the chamber at 
48 h post-transfection. The lower compartment contained 
DMEM-HG with 10% FBS, used as chemoattractant. After 
incubation at 37°C for additional 24 h, migrated cells at 
the base of the inserts were fixed in 100% methanol and 
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stained with 1% crystal violet dye. Non-migrating cells 
on the upper surface of the membrane were removed 
with cotton swabs. Cells were photographed under a 
light microscope at 10x. The area occupied by migrated 
cells in si-DNMT3B and si-NC samples was measured 
by using the ImageJ software (http://imagej.nih.gov/ij/). 
Experiments were carried out three times.
Colony formation assay
For anchorage-dependent colony formation assays, 
si-DNMT3B or si-NC transfected RD cells were plated in 
6-well plates at 4×103 cells/well and cultured for 8 days. 
Colonies were fixed in 100% methanol and stained with 
1% crystal violet dye in methanol and photographed. To 
quantify colonies, crystal violet was solubilized in 30% 
acetic acid in water for 15 min at RT and absorbance 
was measured using the Biochrom Libra S22 UV/VIS 
spectrophotometer (Biochrom, Berlin, DE) at wavelength 
of 595 nm; 30% acetic acid in water was used as the 
blank. Colony formation capacity in si-DNMT3B cells in 
comparison to si-NC samples was calculated as follow: 
(ODsi-NC - ODsi-DNMT3B / ODsi-NC) x 100%, having three 
determinations per experiment. Assays were carried out 
three times.
U0126 treatment
RD and TE671 cells were seeded at 4x105 cells/
well in 6-well plates. After 24 h, the MEK/ERK 
inhibitor U0126 (Santa Cruz Biotechnology) was added 
to a final concentration of 10 μM. Following different 
times of treatment, cells were collected for western blot 
experiments. Mocked control cells were treated with 
DMSO.
Protein extracts and western blot analysis
RD and TE671 cells, transfected with siRNAs 
or treated with U0126, were lysed in RIPA buffer, 
as previously described [72]. Experiments were 
performed at different times after siRNA transfection 
or drug treatment. Total protein extracts (30 μg) were 
separated on 8-12 % sodium dodecyl sulfate (SDS)-
polyacrylamide gel and transferred onto polyvinylidene 
fluoride (PVDF) membranes (EMD Millipore 
Corporation, Billerica, MA). Filters were blocked in 5 % 
not-fat milk or BSA and incubated over-night at +4 °C 
with the following primary antibodies: Bcl-XL, Cyclin 
B1, Cyclin E2, DNMT3B, E2F1, p21 and p27 by Santa 
Cruz Biotechnology; cleaved PARP, MYOD1, Myogenin 
and MyHC by EMD Millipore Corporation; DNMT1 and 
DNMT3A by GeneTex, Irvine, CA; Cyclin D1 by MBL 
International, Woburn, MA; phospho-pRB at Ser807/811 
(p-RB), total RB, phospho-p38 at Thr180/Tyr182 and 
total p38 by Cell Signalling Technology, Danvers, MA. 
Appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Santa Cruz Biotechnology) 
were used for 1 h at RT. Protein signals were detected 
using WesternBright ECL kit (Advansta, Menlo Park, 
CA), according to the manufacturer’s instructions, and 
visualized by ChemiDoc XRS+ (Bio-Rad). Tubulin 
(Sigma-Aldrich) was used as a normalization control for 
equal loading. Densitometry was performed to quantify 
changes in protein expression using the Image Lab 5.1 
software (Bio-Rad). Briefly, signal intensity for each 
band was calculated by the local subtraction method. 
DNMT3B protein levels in si-DNMT3B samples were 
then normalized and reported as relative expression with 
respect to si-NC cells. All experiments were carried out 
at least three times.
Immunofluorescence
Immunofluorescence experiments were performed 
as previously described [72]. Briefly, RD and TE671 
cells transfected with DNMT3B or NC siRNAs were 
cultured for 48 h before plating 105 cells per well in 24-
well plates with 2% gelatine-coated glasses. After one 
additional day, cells were fixed in 4% paraformaldehyde 
for 30 min and incubated with the following primary 
antibodies: Cyclin B1, DNMT3B, E2F1 and p21 (Santa 
Cruz Biotechnology); MYOD1 and MyHC (EMD 
Millipore Corporation); Cyclin D1 (MBL International); 
p-RB (Cell Signalling Technology). Appropriate 
Texas Red-coniugated secondary antibodies (Jackson 
ImmunoResearch, West Grove, PA,) were used. Nuclei 
were counter-stained with 1 μg/ml 4′, 6-diamido-2-
phenylindole dihydrochloride (DAPI, Sigma-Aldrich). 
Labelled cover-slips mounted in Moviol were acquired 
with Zeiss ApoTome and Axiovision software (Carl Zeiss) 
using a 40x magnification. Experiments were replicated 
twice.
Statistical analysis
Data were expressed as mean ± standard deviation 
(SD) of each condition. Statistical significance between 
groups was assessed by Student’s t-test and probability (p) 
values of less than 0.05 were accepted as significant.
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